The potential effects of anti-diabetic medications on myocardial ischemia-reperfusion injury

Yumei Ye, Jose R. Perez-Polo, David Aguilar, Yochai Birnbaum

Research output: Contribution to journalArticle

78 Citations (Scopus)

Abstract

Heart disease and stroke account for 65% of the deaths in people with diabetes mellitus (DM). DM and hyperglycemia cause systemic inflammation, endothelial dysfunction, a hypercoagulable state with impaired fibrinolysis and increased platelet degranulation, and reduced coronary collateral blood flow. DM also interferes with myocardial protection afforded by preconditioning and postconditioning. Newer anti-diabetic agents should not only reduce serum glucose and HbA 1c levels, but also improve cardiovascular outcomes. The older sulfonylurea agent, glyburide, abolishes the benefits of ischemic and pharmacologic preconditioning, but newer sulfonylurea agents, such as glimepiride, may not interfere with preconditioning. GLP-1 analogs and sitagliptin, an oral dipeptidyl peptidase IV inhibitor, limit myocardial infarct size in animal models by increasing intracellular cAMP levels and activating protein kinase A, whereas metformin protects the heart by activating AMP-activated protein kinase. Both thiazolidinediones (rosiglitazone and pioglitazone) limit infarct size in animal models. The protective effect of pioglitazone is dependent on downstream activation of cytosolic phospholipase A 2 and cyclooxygenase-2 with subsequent increased production of 15-epi-lipoxin A 4, prostacyclin and 15-d-PGJ 2. We conclude that agents used to treat DM have additional actions that have been shown to affect the ability of the heart to protect itself against ischemia-reperfusion injury in preclinical models. However, the effects of these agents in doses used in the clinical setting to minimize ischemia-reperfusion injury and to affect clinical outcomes in patients with DM have yet to be shown. The clinical implications as well as the mechanisms of protection should be further studied.

Original languageEnglish (US)
Pages (from-to)925-952
Number of pages28
JournalBasic Research in Cardiology
Volume106
Issue number6
DOIs
StatePublished - Nov 2011

Fingerprint

Myocardial Reperfusion Injury
Reperfusion Injury
pioglitazone
Myocardial Ischemia
Diabetes Mellitus
rosiglitazone
glimepiride
Animal Models
Lipoxins
Dipeptidyl-Peptidase IV Inhibitors
Thiazolidinediones
Ischemic Preconditioning
AMP-Activated Protein Kinases
Glucagon-Like Peptide 1
Glyburide
Phospholipases A
Metformin
Fibrinolysis
Epoprostenol
Cyclooxygenase 2

Keywords

  • Animal models
  • Anti-diabetic agents
  • Infarct size
  • Ischemia reperfusion injury
  • Type-2 diabetes mellitus

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Physiology (medical)
  • Physiology

Cite this

The potential effects of anti-diabetic medications on myocardial ischemia-reperfusion injury. / Ye, Yumei; Perez-Polo, Jose R.; Aguilar, David; Birnbaum, Yochai.

In: Basic Research in Cardiology, Vol. 106, No. 6, 11.2011, p. 925-952.

Research output: Contribution to journalArticle

Ye, Yumei ; Perez-Polo, Jose R. ; Aguilar, David ; Birnbaum, Yochai. / The potential effects of anti-diabetic medications on myocardial ischemia-reperfusion injury. In: Basic Research in Cardiology. 2011 ; Vol. 106, No. 6. pp. 925-952.
@article{ba225baa627449d3a2593ee99ffe0e5a,
title = "The potential effects of anti-diabetic medications on myocardial ischemia-reperfusion injury",
abstract = "Heart disease and stroke account for 65{\%} of the deaths in people with diabetes mellitus (DM). DM and hyperglycemia cause systemic inflammation, endothelial dysfunction, a hypercoagulable state with impaired fibrinolysis and increased platelet degranulation, and reduced coronary collateral blood flow. DM also interferes with myocardial protection afforded by preconditioning and postconditioning. Newer anti-diabetic agents should not only reduce serum glucose and HbA 1c levels, but also improve cardiovascular outcomes. The older sulfonylurea agent, glyburide, abolishes the benefits of ischemic and pharmacologic preconditioning, but newer sulfonylurea agents, such as glimepiride, may not interfere with preconditioning. GLP-1 analogs and sitagliptin, an oral dipeptidyl peptidase IV inhibitor, limit myocardial infarct size in animal models by increasing intracellular cAMP levels and activating protein kinase A, whereas metformin protects the heart by activating AMP-activated protein kinase. Both thiazolidinediones (rosiglitazone and pioglitazone) limit infarct size in animal models. The protective effect of pioglitazone is dependent on downstream activation of cytosolic phospholipase A 2 and cyclooxygenase-2 with subsequent increased production of 15-epi-lipoxin A 4, prostacyclin and 15-d-PGJ 2. We conclude that agents used to treat DM have additional actions that have been shown to affect the ability of the heart to protect itself against ischemia-reperfusion injury in preclinical models. However, the effects of these agents in doses used in the clinical setting to minimize ischemia-reperfusion injury and to affect clinical outcomes in patients with DM have yet to be shown. The clinical implications as well as the mechanisms of protection should be further studied.",
keywords = "Animal models, Anti-diabetic agents, Infarct size, Ischemia reperfusion injury, Type-2 diabetes mellitus",
author = "Yumei Ye and Perez-Polo, {Jose R.} and David Aguilar and Yochai Birnbaum",
year = "2011",
month = "11",
doi = "10.1007/s00395-011-0216-6",
language = "English (US)",
volume = "106",
pages = "925--952",
journal = "Basic Research in Cardiology",
issn = "0300-8428",
publisher = "D. Steinkopff-Verlag",
number = "6",

}

TY - JOUR

T1 - The potential effects of anti-diabetic medications on myocardial ischemia-reperfusion injury

AU - Ye, Yumei

AU - Perez-Polo, Jose R.

AU - Aguilar, David

AU - Birnbaum, Yochai

PY - 2011/11

Y1 - 2011/11

N2 - Heart disease and stroke account for 65% of the deaths in people with diabetes mellitus (DM). DM and hyperglycemia cause systemic inflammation, endothelial dysfunction, a hypercoagulable state with impaired fibrinolysis and increased platelet degranulation, and reduced coronary collateral blood flow. DM also interferes with myocardial protection afforded by preconditioning and postconditioning. Newer anti-diabetic agents should not only reduce serum glucose and HbA 1c levels, but also improve cardiovascular outcomes. The older sulfonylurea agent, glyburide, abolishes the benefits of ischemic and pharmacologic preconditioning, but newer sulfonylurea agents, such as glimepiride, may not interfere with preconditioning. GLP-1 analogs and sitagliptin, an oral dipeptidyl peptidase IV inhibitor, limit myocardial infarct size in animal models by increasing intracellular cAMP levels and activating protein kinase A, whereas metformin protects the heart by activating AMP-activated protein kinase. Both thiazolidinediones (rosiglitazone and pioglitazone) limit infarct size in animal models. The protective effect of pioglitazone is dependent on downstream activation of cytosolic phospholipase A 2 and cyclooxygenase-2 with subsequent increased production of 15-epi-lipoxin A 4, prostacyclin and 15-d-PGJ 2. We conclude that agents used to treat DM have additional actions that have been shown to affect the ability of the heart to protect itself against ischemia-reperfusion injury in preclinical models. However, the effects of these agents in doses used in the clinical setting to minimize ischemia-reperfusion injury and to affect clinical outcomes in patients with DM have yet to be shown. The clinical implications as well as the mechanisms of protection should be further studied.

AB - Heart disease and stroke account for 65% of the deaths in people with diabetes mellitus (DM). DM and hyperglycemia cause systemic inflammation, endothelial dysfunction, a hypercoagulable state with impaired fibrinolysis and increased platelet degranulation, and reduced coronary collateral blood flow. DM also interferes with myocardial protection afforded by preconditioning and postconditioning. Newer anti-diabetic agents should not only reduce serum glucose and HbA 1c levels, but also improve cardiovascular outcomes. The older sulfonylurea agent, glyburide, abolishes the benefits of ischemic and pharmacologic preconditioning, but newer sulfonylurea agents, such as glimepiride, may not interfere with preconditioning. GLP-1 analogs and sitagliptin, an oral dipeptidyl peptidase IV inhibitor, limit myocardial infarct size in animal models by increasing intracellular cAMP levels and activating protein kinase A, whereas metformin protects the heart by activating AMP-activated protein kinase. Both thiazolidinediones (rosiglitazone and pioglitazone) limit infarct size in animal models. The protective effect of pioglitazone is dependent on downstream activation of cytosolic phospholipase A 2 and cyclooxygenase-2 with subsequent increased production of 15-epi-lipoxin A 4, prostacyclin and 15-d-PGJ 2. We conclude that agents used to treat DM have additional actions that have been shown to affect the ability of the heart to protect itself against ischemia-reperfusion injury in preclinical models. However, the effects of these agents in doses used in the clinical setting to minimize ischemia-reperfusion injury and to affect clinical outcomes in patients with DM have yet to be shown. The clinical implications as well as the mechanisms of protection should be further studied.

KW - Animal models

KW - Anti-diabetic agents

KW - Infarct size

KW - Ischemia reperfusion injury

KW - Type-2 diabetes mellitus

UR - http://www.scopus.com/inward/record.url?scp=84856702326&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84856702326&partnerID=8YFLogxK

U2 - 10.1007/s00395-011-0216-6

DO - 10.1007/s00395-011-0216-6

M3 - Article

C2 - 21892746

AN - SCOPUS:84856702326

VL - 106

SP - 925

EP - 952

JO - Basic Research in Cardiology

JF - Basic Research in Cardiology

SN - 0300-8428

IS - 6

ER -